CMHSF (Comprehensive Healthcare Systems) Research & Development: $1.05 Mil (TTM As of Mar. 2026)


CMHSF Comprehensive Healthcare Systems Inc CMHSF
26 GF Score
Price $0.38
GF Value $0.08
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Comprehensive Healthcare Systems Research & Development?

Comprehensive Healthcare Systems CMHSF +10.45% 26 Research & Development is $1.05 Mil as of Mar. 2026. GuruFocus rates CMHSF with a GF Score™ of 26/100 and a GF Value™ of $0.08 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Comprehensive Healthcare Systems's Research & Development for the three months ended in Mar. 2026 was $0.40 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $1.05 Mil.

Comprehensive Healthcare Systems  (OTCPK:CMHSF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Comprehensive Healthcare Systems Research & Development Related Terms

Comprehensive Healthcare Systems Research & Development Historical Data

* Premium members only.

The historical data trend for Comprehensive Healthcare Systems's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Comprehensive Healthcare Systems Research & Development Chart

Comprehensive Healthcare Systems Annual Data
Trend Jan19 Jan20 Jan21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.00 0.49 0.49 0.52 0.76

Comprehensive Healthcare Systems Quarterly Data
Apr21 Jul21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.11 0.15 0.13 0.38 0.40
CMHSF
26GF Score
Comprehensive Healthcare Systems Inc CMHSF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Comprehensive Healthcare Systems Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.05 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $1.05 Mil mean?
Comprehensive Healthcare Systems (CMHSF) has a Research & Development of $1.05 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Comprehensive Healthcare Systems and its competitors.
Is Comprehensive Healthcare Systems' Research & Development too high?
Comprehensive Healthcare Systems' current Research & Development is $1.05 Mil. Overall, Comprehensive Healthcare Systems has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Comprehensive Healthcare Systems' Research & Development compare to VEEV and BTSG?
Comprehensive Healthcare Systems' Research & Development of $1.05 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Comprehensive Healthcare Systems and its competitors. Comprehensive Healthcare Systems's current Research & Development is $1.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Comprehensive Healthcare Systems stock overvalued right now?
Based on GuruFocus' analysis, Comprehensive Healthcare Systems (CMHSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.08, compared to a current price of $0.38 — trading 374.2% above its estimated fair value. The current Research & Development is $1.05 Mil. Comprehensive Healthcare Systems' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Comprehensive Healthcare Systems (CMHSF), the current Research & Development is $1.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Comprehensive Healthcare Systems (CMHSF) Overvalued in 2026?

Based on GuruFocus' analysis, Comprehensive Healthcare Systems stock appears to be overvalued. The current stock price of $0.38 is trading 374.2% above its estimated GF Value™ of $0.08. GuruFocus considers Comprehensive Healthcare Systems to be Significantly Overvalued.

Key valuation signals for CMHSF:

  • Research & Development: $1.05 Mil
  • GF Value™: $0.08 vs. price of $0.38 (374.2% above fair value)
  • GF Score™: 26/100 with 5 warning signs

No single metric tells the full story. See the CMHSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Comprehensive Healthcare Systems Business Description

Other Exchanges CHS:Canada
Address 515 Plainfield Avenue, Suite 103, Edison, NJ, USA, 08817
Comprehensive Healthcare Systems Inc is a vertically integrated software as a services (SaaS) company focused on digitizing healthcare with Healthcare Benefits Administration solutions, providing reliable and high-volume transaction-capable systems. The company's Novus 360 Healthcare Welfare and Benefits Administration (HWBA) SaaS platform is used by clients for all aspects of healthcare benefits administration (including self-funded employers, providers, and labor unions), providing healthcare administrative software and technology-enabled services. It provides healthcare administrative software, licensing and maintenance services to various interests in the healthcare industry, including insurance companies, hospitals, doctors and labor unions. It operates in single segment.
26GF Score

Get the complete analysis for CMHSF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price
$0.08
GF Value